細菌性肺炎市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、治療方法、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球細菌性肺炎市場預計將從 2025 年的 26.4 億美元大幅成長至 2031 年的 40.2 億美元，複合年成長率為 7.26%。

這個市場主要針對細菌性肺炎，嚴重的下呼吸道感染疾病，通常由肺炎鏈球菌引起，會導致肺泡發炎和儲存。主要成長要素包括全球老年人口不斷增加，老年人由於免疫力減弱而更容易感染疾病，以及慢性呼吸系統疾病（如慢性阻塞性肺病(COPD)）的盛行率不斷上升。根據美國肺臟協會2025年的數據，65歲及以上成年人因肺炎球菌性肺炎住院的可能性是18至49歲人群的10倍以上，這凸顯了為老年人提供有效治療方法的緊迫性。此外，強力的政府政策支持國家免疫規劃對於維持預防措施的需求至關重要。然而，抗菌素抗藥性的迅速蔓延是該市場面臨的主要挑戰，阻礙了整體市場成長。多重抗藥性細菌會降低傳統抗生素的療效，使患者照護更加複雜，並需要對新藥研發進行大量投資。

市場促進因素

全球細菌性肺炎市場的主要促進因素是全球免疫宣傳活動運動的加強，這主要得益於新一代結合疫苗的研發，這些疫苗能夠提供更廣泛的保護，抵禦多種血清型。監管機構正在加快核准這些先進的生物製藥，以填補成人和兒童在抵禦侵襲性細菌菌株方面存在的保護缺口。例如，默克公司於2024年6月宣布，美國食品藥物管理局（FDA）已批准其新型21價結合疫苗CAPVAXIVE上市，該疫苗特異性核准導致50歲及以上人群中約84%侵襲性肺炎鏈球菌感染的血清型。這些旨在改善預防醫學的努力也反映在國際疫苗的普及率上。根據世界衛生組織（世衛組織）2024年7月發布的《免疫接種率報告》，預計到2023年底，全球肺炎球菌結合疫苗第三劑接種率將達到65%，這反映了透過廣泛接種疫苗來減輕疾病負擔的持續努力。同時，全球細菌性肺炎的盛行率正在上升，尤其是在新冠疫情後呼吸道病原體捲土重來的情況下，這推動了對治療和診斷工具的需求。醫療系統面臨著患者數量的顯著增加，尤其是在感染風險較高的年輕人群體中，這需要增加抗生素供應並擴大醫院基礎設施。這正在推動市場成長，並有助於緩解抗菌素抗藥性帶來的挑戰。

市場挑戰

抗菌素抗藥性是全球細菌性肺炎市場成長的直接障礙，嚴重削弱了現有藥物治療的臨床療效和商業性潛力。隨著細菌病原體對標準一線抗生素的抗藥性日益增強，市場面臨嚴峻的療效挑戰，許多廉價的大規模生產的學名藥效力下降。這種療效下降導致市場劇烈波動，迫使醫療機構放棄既定的治療指南，轉而採用替代療法。然而，這些替代療法往往難以獲得，或具有更高的毒性風險。因此，市場分散，由於標準藥物頻繁失效，處方量不穩定，進而阻礙了整個產業的擴張。近期對主要呼吸道病原體的監測數據也印證了這項挑戰的嚴峻性。例如，世界衛生組織（WHO）報告稱，到2025年，肺炎克雷伯菌（一種眾所周知的嚴重肺炎病原體）對第三代頭孢菌素的全球抗藥性將超過55%。如此高的抗藥性極大地縮小了傳統抗生素的潛在市場，迫使該行業將資源從強化現有治療方法轉向探索高風險的新型化合物。因此，全球細菌性肺炎市場正面臨瓶頸，阻礙其穩定發展。

市場趨勢

將人工智慧 (AI) 引入肺炎的影像診斷領域，顯著提高了診斷準確率，有效解決了人類解讀複雜 X 光片時固有的挑戰。先進的演算法能夠識別指示病原體引起的細微變化，從而實現更快、更精準的治療性介入。例如，2025 年 1 月發表在《新圖譜》(New Atlas) 上的一篇報導介紹了一種新的 AI 模型，該模型在區分肺炎與其他呼吸道疾病方面達到了 96.57% 的診斷準確率，顯著優於傳統技術。這項技術的應用正在加速 AI 工具在醫療保健領域的普及。 AI 工具可作為值得信賴的輔助診斷工具，最大限度地減少診斷錯誤，並最佳化繁忙醫療環境中的資源分配。同時，呼吸道病原體症候群檢測的日益普及，透過快速區分病毒和細菌混合感染疾病，從根本上改變了臨床管理。這一趨勢包括從單一病原體檢測轉向多分子檢測，從而簡化呼吸道疾病爆發期間的患者評估流程。根據Cepheid公司2025年1月報告，該公司一種快速分子檢測方法已獲得FDA核准，該方法可從單一檢體中同時識別四種病毒標靶，包括SARS-CoV-2和流感病毒。使用這種綜合檢測方法將縮短診斷時間，減少不必要的抗生素處方，並最佳化醫療機構的隔離流程。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細菌性肺炎市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（社區型肺炎（CAP）、醫院獲得性肺炎（HAP））
  • 治療方法（疫苗、藥物）
  • 給藥途徑（口服、皮下注射、其他）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細菌性肺炎市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲細菌性肺炎市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區細菌性肺炎市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲細菌性肺炎市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲細菌性肺炎市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球細菌性肺炎市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Innoviva Inc
• Pfizer Inc.
• Merck & Co., Inc.
• Melinta Therapeutics LLC
• Evopoint Biosciences
• Aridis Pharmaceuticals Inc.
• Cumberland Pharmaceuticals Inc.
• Eagle Pharmaceuticals, Inc.
• Clarametyx Biosciences
• Basilea Pharmaceutica Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Bacterial Pneumonia Market is projected to expand significantly, rising from USD 2.64 Billion in 2025 to USD 4.02 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.26%. This market addresses bacterial pneumonia, a serious lower respiratory infection often caused by Streptococcus pneumoniae, leading to inflammation and fluid in the lung's air sacs. Key growth catalysts include the increasing global elderly population, who are more susceptible to infections due to weakened immune systems, and the rising incidence of chronic respiratory conditions like COPD.Data from the American Lung Association in 2025 indicated that adults aged 65 and above were over ten times more likely to require hospitalization for pneumococcal pneumonia compared to those aged 18 to 49, highlighting an urgent need for effective treatments in older populations. Furthermore, strong government policies supporting national immunization programs are fundamental to maintaining demand for preventive solutions. However, the market faces a substantial challenge from the swift rise of antimicrobial resistance, as multidrug-resistant bacteria diminish the effectiveness of conventional antibiotics, complicating patient care and mandating substantial investment in new drug development, thereby hindering overall market growth.

Market Driver

A key driver for the Global Bacterial Pneumonia Market is the intensification of worldwide immunization and vaccination campaigns, significantly boosted by the development of next-generation conjugate vaccines offering broader protection against various serotypes. Regulatory agencies are fast-tracking approvals for these advanced biological products to close existing gaps in both adult and pediatric defense against aggressive bacterial strains. For example, Merck reported in June 2024 that the U.S. FDA approved a new 21-valent conjugate vaccine, CAPVAXIVE, specifically targeting serotypes responsible for roughly 84% of invasive pneumococcal disease in individuals aged 50 and older.This commitment to improved preventive care is also evident in widespread international deployment, with the World Health Organization's July 2024 report on Immunization Coverage indicating that global coverage for the third dose of pneumococcal conjugate vaccine reached an estimated 65% by the end of 2023, reflecting ongoing efforts to lessen the disease burden through extensive vaccination. Simultaneously, the increasing global prevalence of bacterial pneumonia, particularly with the post-pandemic resurgence of respiratory pathogens, is fueling demand for both treatment and diagnostic tools. Healthcare systems are experiencing a significant surge in patient numbers, especially among susceptible younger groups, necessitating greater supplies of antibiotics and hospital infrastructure, which in turn drives market expansion and helps mitigate the challenges presented by antimicrobial resistance.

Market Challenge

Antimicrobial resistance poses a direct impediment to the growth of the Global Bacterial Pneumonia Market, significantly undermining the clinical effectiveness and commercial future of existing pharmaceutical treatments. As bacterial pathogens increasingly develop resistance to standard first-line antibiotics, the market is confronted with a severe efficacy challenge, rendering many inexpensive, high-volume generic drugs ineffective. This loss of effectiveness creates considerable market volatility, compelling healthcare providers to forsake established treatment guidelines in favor of alternative therapies, which are frequently less available or carry greater toxicity risks.Consequently, the market becomes fragmented, with the frequent failure of standard drugs discouraging consistent prescription volumes and thereby impeding the sector's overall expansion. The severity of this challenge is evident in recent surveillance data concerning major respiratory pathogens; for instance, the World Health Organization reported in 2025 that global resistance to third-generation cephalosporins in Klebsiella pneumoniae, a bacterium commonly linked to severe pneumonia, surpassed 55%. Such high resistance levels dramatically shrink the potential market for traditional antibiotic categories, forcing the industry to reallocate resources towards risky research into new compounds instead of enhancing existing treatments, thus forming a bottleneck that obstructs the steady advancement of the Global Bacterial Pneumonia Market.

Market Trends

The integration of Artificial Intelligence (AI) into pneumonia imaging and detection is significantly advancing diagnostic accuracy, effectively addressing the inherent human challenges in interpreting intricate radiographs. Sophisticated algorithms can now discern nuanced patterns indicative of pathogen-induced changes, enabling quicker and more precise therapeutic interventions. For instance, a New Atlas article from January 2025 highlighted a new AI model achieving 96.57% diagnostic accuracy, considerably surpassing conventional techniques in distinguishing pneumonia from other respiratory ailments.This technological validation is accelerating the adoption of AI tools into clinical practices, where they function as dependable second readers, thereby minimizing diagnostic inaccuracies and improving resource allocation in busy healthcare environments. Simultaneously, the growing adoption of syndromic panel testing for respiratory pathogens is fundamentally transforming clinical management by facilitating the swift differentiation of co-occurring viral and bacterial infections. This trend involves moving from single-pathogen tests to multiplexed molecular assays, which streamline patient assessment during periods of high respiratory illness. As reported by Cepheid in January 2025, the company obtained FDA approval for a rapid molecular test that can simultaneously identify four different viral targets, including SARS-CoV-2 and influenza, from a single sample. The use of these comprehensive panels shortens diagnosis times, reduces inappropriate antibiotic prescriptions, and refines isolation procedures in healthcare settings.

Key Market Players

• Innoviva Inc
• Pfizer Inc.
• Merck & Co., Inc.
• Melinta Therapeutics LLC
• Evopoint Biosciences
• Aridis Pharmaceuticals Inc.
• Cumberland Pharmaceuticals Inc.
• Eagle Pharmaceuticals, Inc.
• Clarametyx Biosciences
• Basilea Pharmaceutica Ltd

Report Scope

In this report, the Global Bacterial Pneumonia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bacterial Pneumonia Market, By Type

• Community-Acquired Pneumonia (CAP)
• Hospital-Acquired Pneumonia (HAP)

Bacterial Pneumonia Market, By Treatments

• Vaccines
• Drugs

Bacterial Pneumonia Market, By Route of Administration

• Oral
• Subcutaneous
• Other

Bacterial Pneumonia Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Bacterial Pneumonia Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Pneumonia Market.

Available Customizations:

Global Bacterial Pneumonia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bacterial Pneumonia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP))
  • 5.2.2. By Treatments (Vaccines, Drugs)
  • 5.2.3. By Route of Administration (Oral, Subcutaneous, Other)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Bacterial Pneumonia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatments
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bacterial Pneumonia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatments
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Bacterial Pneumonia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatments
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Bacterial Pneumonia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatments
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Bacterial Pneumonia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatments
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bacterial Pneumonia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatments
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Bacterial Pneumonia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatments
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Bacterial Pneumonia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatments
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Bacterial Pneumonia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatments
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Bacterial Pneumonia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatments
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Bacterial Pneumonia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatments
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bacterial Pneumonia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatments
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Bacterial Pneumonia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatments
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Bacterial Pneumonia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatments
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Bacterial Pneumonia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatments
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Bacterial Pneumonia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatments
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Bacterial Pneumonia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatments
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bacterial Pneumonia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatments
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Bacterial Pneumonia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatments
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Bacterial Pneumonia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatments
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Bacterial Pneumonia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatments
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bacterial Pneumonia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatments
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Bacterial Pneumonia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatments
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Bacterial Pneumonia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatments
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bacterial Pneumonia Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Innoviva Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Merck & Co., Inc.
• 15.4. Melinta Therapeutics LLC
• 15.5. Evopoint Biosciences
• 15.6. Aridis Pharmaceuticals Inc.
• 15.7. Cumberland Pharmaceuticals Inc.
• 15.8. Eagle Pharmaceuticals, Inc.
• 15.9. Clarametyx Biosciences
• 15.10. Basilea Pharmaceutica Ltd

16. Strategic Recommendations

17. About Us & Disclaimer